Surgery Open Science (Jul 2020)

Does resection improve overall survival for intrahepatic cholangiocarcinoma with nodal metastases?

  • Patrick J. Sweigert, MD,
  • Emanuel Eguia, MD, MS, MHA,
  • Haroon Janjua, MS,
  • Sean P. Nassoiy, DO, MS,
  • Lawrence M. Knab, MD,
  • Gerard Abood, MD, MS,
  • Paul C. Kuo, MD, MS, MBA,
  • Marshall S. Baker, MD, MBA

Journal volume & issue
Vol. 2, no. 3
pp. 107 – 112

Abstract

Read online

Background: The potential benefit of surgical resection of intrahepatic cholangiocarcinoma in patients with locoregionally advanced disease has not been definitively determined. Methods: The National Cancer Database was queried to identify patients with clinical evidence of node-positive intrahepatic cholangiocarcinoma. Resected patients were stratified by margin status and lymph node ratio (nodes positive to nodes harvested). Risk of death was determined using Cox regression models and Kaplan-Meier survival functions. Results: A total of 1,425 patients with T(any)N1M0 intrahepatic cholangiocarcinoma were identified. Two hundred twelve (14.9%) underwent surgical resection. On multivariable Cox regression, R0 resection afforded a survival benefit regardless of lymph node ratio (lymph node ratio > 0.5: hazard ratio 0.466, 95% confidence interval 0.304–0.715; lymph node ratio ≤ 0.5: hazard ratio 0.444, 95% confidence interval 0.322–0.611), whereas a survival benefit was only seen in R1 patients with lymph node ratio ≤ 0.5 (hazard ratio 0.470, 95% confidence interval 0.316–0.701). On Kaplan-Meier, median survival was 11.6 months with chemotherapy, 15.7 months with R0 resection in lymph node ratio > 0.5, and 22.2 months with R0 resection in lymph node ratio ≤ 0.5 (P < .001). Discussion: Margin negative resection is associated with a risk-adjusted survival benefit for patients with clinically N1 intrahepatic cholangiocarcinoma regardless of the degree of regional lymph node involvement.